Stockscreener 앱 받기
7.68
1.84%
0.14
시간 외 거래:
7.75
0.07
+0.91%
전일 마감가:
$7.54
열려 있는:
$7.55
하루 거래량:
1.97M
Relative Volume:
1.42
시가총액:
$598.61M
수익:
$400.05M
순이익/손실:
$181.01M
주가수익비율:
3.6584
EPS:
2.0993
순현금흐름:
$194.58M
1주 성능:
+1.98%
1개월 성능:
-8.80%
6개월 성능:
+6.50%
1년 성능:
-40.61%
1일 변동 폭
$7.4801
$8.11
1주일 범위
$7.10
$8.98
52주 변동 폭
$6.125
$14.96
CorMedix Inc Stock (CRMD) Company Profile
명칭
CorMedix Inc
전화
908-517-9500
주소
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
7.68 | 587.70M | 400.05M | 181.01M | 194.58M | 2.0993 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 업그레이드 | D. Boral Capital | Hold → Buy |
| 2025-06-30 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2025-06-30 | 개시 | H.C. Wainwright | Buy |
| 2025-03-07 | 개시 | Leerink Partners | Outperform |
| 2025-01-13 | 개시 | D. Boral Capital | Buy |
| 2024-08-26 | 개시 | Rodman & Renshaw | Buy |
| 2023-08-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-02-17 | 개시 | Needham | Buy |
| 2020-09-29 | 개시 | JMP Securities | Mkt Outperform |
| 2020-09-21 | 개시 | Truist | Buy |
| 2019-12-18 | 개시 | B. Riley FBR | Buy |
| 2019-03-26 | 재확인 | H.C. Wainwright | Buy |
| 2018-12-06 | 개시 | ROTH Capital | Buy |
| 2017-09-25 | 재확인 | H.C. Wainwright | Buy |
| 2017-08-10 | 재확인 | Rodman & Renshaw | Buy |
| 2017-05-05 | 재확인 | Rodman & Renshaw | Buy |
| 2016-11-11 | 재확인 | FBR & Co. | Outperform |
| 2016-03-17 | 재확인 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | FBR Capital | Outperform |
| 2015-11-16 | 재확인 | ROTH Capital | Neutral |
| 2015-10-29 | 재확인 | ROTH Capital | Neutral |
| 2015-05-06 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2014-12-08 | 재확인 | ROTH Capital | Buy |
| 2011-10-03 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
CorMedix Inc 주식(CRMD)의 최신 뉴스
CorMedix (NASDAQ:CRMD) Shares Up 7.3% on Analyst Upgrade - marketbeat.com
FY2026 EPS Estimates for CorMedix Raised by HC Wainwright - marketbeat.com
(CRMD) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
CorMedix Inc (CRMD) Stock News Today - TradingKey
CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market - Stocktwits
CorMedix Stock Jumps on Strong DefenCath Sales - Sahm
Full Transcript: Cormedix Q2 2026 Earnings Call - Sahm
CorMedix (NASDAQ:CRMD) Shares Down 4.6%Here's Why - marketbeat.com
Royal Bank Of Canada Issues Positive Forecast for CorMedix (NASDAQ:CRMD) Stock Price - marketbeat.com
CorMedix's New Major DefenCath Customer Backs 2026 Volumes, Durability Through 2027, RBC Says - marketscreener.com
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains - The Globe and Mail
RBC Adjusts Price Target on CorMedix to $14 From $13, Maintains Outperform Speculative Risk Rating - Moomoo
CRMD News | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
H.C. Wainwright reiterates CorMedix stock rating on strong quarter By Investing.com - Investing.com India
H.C. Wainwright Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $13 - Moomoo
CorMedix (CRMD) Q2 2026 Earnings Call: Revenue Hits $101.9M, EBITDA Guidance Raised - TradingKey
CorMedix Inc (NASDAQ:CRMD) Receives Average Rating of "Moderate Buy" from Brokerages - marketbeat.com
CorMedix Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
CorMedix Shares Surge 17% as Q2 Revenue Tops $100 Million, EBITDA Outlook Raised - finance.biggo.com
CorMedix Q2 2026 Earnings Call Transcript - MarketBeat
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $15 - Moomoo
CorMedix Inc (NASDAQ: CRMD) Share Price, CRMD Stock News, CRMD Share Price & Updates - kalkine.ca
CorMedix Shares Rise After Q2 Results, Guidance - marketscreener.com
CorMedix (NASDAQ:CRMD) Releases Earnings Results, Beats Estimates By $0.05 EPS - marketbeat.com
CorMedix Q2 revenue hits $101.9M; DEFSEC up 92% YoY - scanx.trade
CorMedix Q2 Earnings Call Highlights - MarketBeat
CorMedix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
CorMedix CEO Expects Supplemental Filing For Fungal Disease Treatment By Q3 – CRMD Stock Sees Best Day In Nearly 10 Months After Earnings Beat - Yahoo Finance
CorMedix earnings beat by $0.06, revenue topped estimates - Investing.com Australia
Earnings call transcript: CorMedix tops Q2 2026 estimates, shares jump 16% - Investing.com Australia
CorMedix (NASDAQ:CRMD) Shares Gap Up Following Earnings Beat - marketbeat.com
CorMedix Announces Q2 2026 Revenue Surge to $101.9 Million and Strong Net Income - Kalkine Media
Accelerant Holdings, CorMedix, Birkenstock And Other Big Stocks Moving Higher On Thursday - Benzinga
CRMD: Q2 revenue and EBITDA soared, with new supply deals and pipeline advances driving raised guidance - TradingView
CorMedix Inc. Reiterates Consolidated Earnings Guidance for the Year 2026 - marketscreener.com
Why is CorMedix stock surging today? By Investing.com - Investing.com South Africa
Transcript : CorMedix Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com
CorMedix Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
CRMD: Q2 revenue and EBITDA soared, with new supply deals and pipeline progress driving raised guidance - TradingView
Why is CorMedix stock surging today? - Investing.com
CorMedix Inc. (CRMD) Stock Price, News, Quote & History - Yahoo! Finance Canada
CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates - Yahoo Finance UK
Form 8K CorMedix Inc For: 13 August By Investing.com - Investing.com Australia
CorMedix Inc. (CRMD) revenue jumps as Melinta deal boosts Q2 2026 profit - Stock Titan
CRMD: Q2 2026 revenue and earnings rose sharply, driven by DefenCath and Melinta portfolio growth - TradingView
CorMedix: Q2 Earnings Snapshot - AOL.com
CorMedix reports Q2 2026 consolidated revenue $101.9M, net income $26.0M, adjusted EBITDA $58.7M - TradingView
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
CorMedix (CRMD) Earnings Date and Reports 2026 - MarketBeat
CorMedix Inc $CRMD Shares Purchased by Hennion & Walsh Asset Management Inc. - marketbeat.com
Cormedix Wins Preliminary OK on Governance Settlement Reforms - The Globe and Mail
CorMedix Inc (CRMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.20%
0.07%
자본화:
|
볼륨(24시간):